Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,068,560
  • Shares Outstanding, K 174,251
  • Annual Sales, $ 838,000 K
  • Annual Income, $ 100,780 K
  • 60-Month Beta 0.80
  • Price/Sales 3.49
  • Price/Cash Flow 26.83
  • Price/Book 3.93
Trade HCM with:

Options Overview Details

View History
  • Implied Volatility 73.28% ( +8.37%)
  • Historical Volatility 80.39%
  • IV Percentile 36%
  • IV Rank 38.16%
  • IV High 126.14% on 01/29/24
  • IV Low 40.66% on 12/22/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 184
  • Open Int (30-Day) 230

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.64 +25.59%
on 03/05/24
19.40 -11.70%
on 03/13/24
+2.54 (+17.41%)
since 02/16/24
3-Month
11.93 +43.54%
on 02/05/24
19.40 -11.70%
on 03/13/24
-0.90 (-4.99%)
since 12/18/23
52-Week
10.68 +60.39%
on 06/23/23
20.73 -17.37%
on 10/30/23
+2.65 (+18.30%)
since 03/17/23

Most Recent Stories

More News
All You Need to Know About HUTCHMED (HCM) Rating Upgrade to Buy

HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

HCM : 17.13 (-2.73%)
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 102.73%: Read This Before Placing a Bet

The consensus price target hints at a 102.7% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

HCM : 17.13 (-2.73%)
Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround

HUTCHMED (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could...

HCM : 17.13 (-2.73%)
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 61.85%: Here's is How to Trade

The mean of analysts' price targets for HUTCHMED (HCM) points to a 61.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

HCM : 17.13 (-2.73%)
Does HUTCHMED (HCM) Have the Potential to Rally 68.08% as Wall Street Analysts Expect?

The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

HCM : 17.13 (-2.73%)
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 17.13 (-2.73%)
HCM.LN : 275.000 (-2.83%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 17.13 (-2.73%)
HCM.LN : 275.000 (-2.83%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 17.13 (-2.73%)
HCM.LN : 275.000 (-2.83%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 17.13 (-2.73%)
HCM.LN : 275.000 (-2.83%)
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today...

HCM : 17.13 (-2.73%)
HCM.LN : 275.000 (-2.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

HUTCHMED Limited is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED Limited, formerly known as HUTCHMED...

See More

Key Turning Points

3rd Resistance Point 18.21
2nd Resistance Point 17.94
1st Resistance Point 17.54
Last Price 17.13
1st Support Level 16.87
2nd Support Level 16.60
3rd Support Level 16.20

See More

52-Week High 20.73
Last Price 17.13
Fibonacci 61.8% 16.89
Fibonacci 50% 15.70
Fibonacci 38.2% 14.52
52-Week Low 10.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar